Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban.
- DOI
- 10.3390/pharmaceutics16111485
- Published
- 2024 Nov 20
- Container
- Pharmaceutics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/pharmaceutics16111485,
title = {Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban.},
author = {Zakowiecki D and Edinger P and Papaioannou M and Wagner M and Hess T and Paszkowska J and Staniszewska M and Myslitska D and Smolenski M and Dobosz J and Garbacz G and Haznar Garbacz D},
year = {2024},
journal = {Pharmaceutics},
doi = {10.3390/pharmaceutics16111485},
url = {https://doi.org/10.3390/pharmaceutics16111485}
}RIS
TY - JOUR TI - Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban. AU - Zakowiecki D AU - Edinger P AU - Papaioannou M AU - Wagner M AU - Hess T AU - Paszkowska J AU - Staniszewska M AU - Myslitska D AU - Smolenski M AU - Dobosz J AU - Garbacz G AU - Haznar Garbacz D PY - 2024 JO - Pharmaceutics DO - 10.3390/pharmaceutics16111485 UR - https://doi.org/10.3390/pharmaceutics16111485 ER -
APA
D, Z., P, E., M, P., M, W., T, H., J, P., M, S., D, M., M, S., J, D., G, G., & D, H. G. (2024). Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban.. Pharmaceutics. https://doi.org/10.3390/pharmaceutics16111485
Source records
- pubmed · retrieved 2026-09-24T22:33:44.914Z